MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00784-022-04484-z

Медицинская библиотека · Clinical oral investigations · 2022

Local delivery of a CXCR3 antagonist decreases the progression of bone resorption induced by LPS injection in a murine model.

Lari Soma, Hiyari Sarah, de Araújo Silva Davi Neto, de Brito Bezerra Beatriz, Ishii Makiko, Monajemzadeh Sepehr, Cui Zhong-Kai, Tetradis Sotirios, Lee Min, Pirih Flavia Q

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

This experimental study was carried out to investigate the effects of locally delivered nanoparticles (AMG-487 NP) containing a CXCR3 antagonist in inhibiting the progression of LPS-induced inflammation, osteoclastic activity, and bone resorption on a murine model.

MATERIALS AND

METHODS

Thirty, 7-week-old C57BL/6 J male mice were used. Inflammatory bone loss was induced by Porphyromonas gingivalis-lipopolysaccharide (P.g.-LPS) injections between the first and second maxillary molars, bilaterally, twice a week for 6 weeks (n = 20). AMG-487 NP were incorporated into a liposome carrier and locally delivered on sites where P.g.-LPS was injected. Control mice (n = 10) were injected with vehicle only. Experimental groups included (1) control, (2) LPS, and (3) LPS + NP. At the end of 1 and 6 weeks, mice were euthanized, maxillae harvested, fixed, and stored for further analysis.

RESULTS

Volumetric bone loss analysis revealed, at 1 week, an increase in bone loss in the LPS group (47.9%) compared to control (27.4%) and LPS + NP (27.8%) groups. H&E staining demonstrated reduced inflammatory infiltrate in the LPS + NP group compared to LPS group. At 6 weeks, volumetric bone loss increased in all groups; however, treatment with the CXCR3 antagonist (LPS + NP) significantly reduced bone loss compared to the LPS group. CXCR3 antagonist treatment significantly reduced osteoclast numbers when compared to LPS group at 1 and 6 weeks.

CONCLUSIONS

This study showed that local delivery of a CXCR antagonist, via nanoparticles, in a bone resorption model, induced by LPS injection, was effective in reducing inflammation, osteoclast numbers, and bone loss.

CLINICAL RELEVANCE: CXCR3 blockade can be regarded as a novel target for therapeutic intervention of bone loss. It can be a safe and convenient method for periodontitis treatment or prevention applicable in clinical practice.

Для цитирования: Lari Soma, Hiyari Sarah, de Araújo Silva Davi Neto, de Brito Bezerra Beatriz, Ishii Makiko, Monajemzadeh Sepehr, Cui Zhong-Kai, Tetradis Sotirios, Lee Min, Pirih Flavia Q. Local delivery of a CXCR3 antagonist decreases the progression of bone resorption induced by LPS injection in a murine model.. Clinical oral investigations. 2022. DOI: 10.1007/s00784-022-04484-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.